BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 26122388)

  • 21. Genomic Landscape and Risk Stratification in Chronic Myelomonocytic Leukemia.
    Hunter A; Padron E
    Curr Hematol Malig Rep; 2021 Jun; 16(3):247-255. PubMed ID: 33660195
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management.
    Parikh SA; Tefferi A
    Am J Hematol; 2012 Jun; 87(6):610-9. PubMed ID: 22615103
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic myelomonocytic leukemia - a review.
    Thomopoulos TP; Bouhla A; Papageorgiou SG; Pappa V
    Expert Rev Hematol; 2021 Jan; 14(1):59-77. PubMed ID: 33275852
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted sequencing aids in identifying clonality in chronic myelomonocytic leukemia.
    Hwang SM; Kim SM; Nam Y; Kim J; Kim S; Ahn YO; Park Y; Yoon SS; Shin S; Kwon S; Lee DS
    Leuk Res; 2019 Sep; 84():106190. PubMed ID: 31377458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How I diagnose and treat chronic myelomonocytic leukemia.
    Patnaik MM
    Haematologica; 2022 Jul; 107(7):1503-1517. PubMed ID: 35236051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia.
    Cui Y; Tong H; Du X; Li B; Gale RP; Qin T; Liu J; Xu Z; Zhang Y; Huang G; Jin J; Fang L; Zhang H; Pan L; Hu N; Qu S; Xiao Z
    Exp Hematol Oncol; 2015; 4():14. PubMed ID: 26019984
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genomic determinants of chronic myelomonocytic leukemia.
    Patel BJ; Przychodzen B; Thota S; Radivoyevitch T; Visconte V; Kuzmanovic T; Clemente M; Hirsch C; Morawski A; Souaid R; Saygin C; Nazha A; Demarest B; LaFramboise T; Sakaguchi H; Kojima S; Carraway HE; Ogawa S; Makishima H; Sekeres MA; Maciejewski JP
    Leukemia; 2017 Dec; 31(12):2815-2823. PubMed ID: 28555081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent Updates on Chronic Myelomonocytic Leukemia.
    Loghavi S; Khoury JD
    Curr Hematol Malig Rep; 2018 Dec; 13(6):446-454. PubMed ID: 30311069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytopenia, dysplasia, and monocytosis: a precursor to chronic myelomonocytic leukemia or a distinct subgroup? Case reports and review of literature.
    Singh ZN; Post GR; Kiwan E; Maddox AM
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11(3):293-7. PubMed ID: 21658659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The detection of SRSF2 mutations in routinely processed bone marrow biopsies is useful in the diagnosis of chronic myelomonocytic leukemia.
    Federmann B; Abele M; Rosero Cuesta DS; Vogel W; Boiocchi L; Kanz L; Quintanilla-Martinez L; Orazi A; Bonzheim I; Fend F
    Hum Pathol; 2014 Dec; 45(12):2471-9. PubMed ID: 25305095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
    Patnaik MM; Lasho TL
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):450-459. PubMed ID: 33275756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes.
    Tiu RV; Sekeres MA
    Curr Opin Hematol; 2014 Mar; 21(2):131-40. PubMed ID: 24378705
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic score including gene mutations in chronic myelomonocytic leukemia.
    Itzykson R; Kosmider O; Renneville A; Gelsi-Boyer V; Meggendorfer M; Morabito M; Berthon C; Adès L; Fenaux P; Beyne-Rauzy O; Vey N; Braun T; Haferlach T; Dreyfus F; Cross NC; Preudhomme C; Bernard OA; Fontenay M; Vainchenker W; Schnittger S; Birnbaum D; Droin N; Solary E
    J Clin Oncol; 2013 Jul; 31(19):2428-36. PubMed ID: 23690417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel therapeutic targets for chronic myelomonocytic leukemia.
    Lasho T; Patnaik MM
    Best Pract Res Clin Haematol; 2021 Mar; 34(1):101244. PubMed ID: 33762099
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.
    Ricci C; Fermo E; Corti S; Molteni M; Faricciotti A; Cortelezzi A; Lambertenghi Deliliers G; Beran M; Onida F
    Clin Cancer Res; 2010 Apr; 16(8):2246-56. PubMed ID: 20371679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapy related-chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML.
    Patnaik MM; Vallapureddy R; Yalniz FF; Hanson CA; Ketterling RP; Lasho TL; Finke C; Al-Kali A; Gangat N; Tefferi A
    Am J Hematol; 2018 Jan; 93(1):65-73. PubMed ID: 29023992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment advances for pediatric and adult onset neoplasms with monocytosis.
    McCullough KB; Kuhn AK; Patnaik MM
    Curr Hematol Malig Rep; 2021 Jun; 16(3):256-266. PubMed ID: 33728588
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia.
    Reinig E; Yang F; Traer E; Arora R; Brown S; Rattray R; Braziel R; Fan G; Press R; Dunlap J
    Am J Clin Pathol; 2016 Apr; 145(4):497-506. PubMed ID: 27124934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CMML: Clinical and molecular aspects.
    Itzykson R; Duchmann M; Lucas N; Solary E
    Int J Hematol; 2017 Jun; 105(6):711-719. PubMed ID: 28455647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study.
    Wassie EA; Itzykson R; Lasho TL; Kosmider O; Finke CM; Hanson CA; Ketterling RP; Solary E; Tefferi A; Patnaik MM
    Am J Hematol; 2014 Dec; 89(12):1111-5. PubMed ID: 25195656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.